

CTI - Neurological Disorders January 2010



Adis Clinical Trials Insight: Presented at Meetings – Neurological Disorders

Annual Meeting of the American Epilepsy Society (63rd : December 2009 : Boston, Massachusetts, USA)

Adis CTI Record	Drug(s)	Purpose	Study Results	Sponsor
1 803004017	Antiepileptic-drugs	This study assessed impairment of verbal and nonverbal cognitive function in 3-year old children following in utero exposure to antiepileptic drugs.	In utero exposure to valproic acid or carbamazepine was associated with impaired verbal and nonverbal cognitive function in 3-year old children of mothers receiving antiepileptic drug monotherapy.	

Adis Clinical Trials Database: Ongoing

The table below highlights the ongoing trials whose status has changed during January 2010

Adis CTI Record	Drug(s)	Study Status	Study Phase	Headline	Sponsor
1 700045965	JNJ-31001074 Ketoconazole	Completed	I	JNJ-31001074 +/- ketoconazole: pharmacokinetics Effect of ketoconazole on the pharmacokinetics of JNJ-31001074 In volunteers	Johnson & Johnson Pharmaceutical Research & Development
2 700031234	DP-b99	Recruiting	III	DP b99: therapeutic use Stroke Phase III trial in patients with acute ischaemic stroke	D-Pharm, D-Pharma
3 700048521	EVP-6124	Recruiting	II	EVP 6124: adverse reactions Various toxicities In patients with schizophrenia or schizoaffective disorder receiving stable atypical antipsychotic therapy	EnVivo Pharmaceuticals
4 700011388	Methylphenidate Modafinil	Completed	III	Methylphenidate vs modafinil: therapeutic use Cognition disorders Phase III trial in patients with primary brain tumours undergoing chemotherapy	
5 700035698	Topiramate	Completed	II	Topiramate: therapeutic use Drug-induced dyskinesia In patients with Parkinson's disease receiving levodopa	

CTI - Neurological Disorders January 2010



Adis CTI Record	Drug(s)	Study Status	Study Phase	Headline	Sponsor
6 700024015	Laquinimod	Active, no longer recruiting	III	Laquinimod: therapeutic use Multiple sclerosis Pivotal phase III trial of oral laquinimod in patients with relapsing-remitting disease: ALLEGRO trial	Active Biotech, Teva Pharmaceutical Industries
7 700038965	Gabapentin	Recruiting	IV	Gabapentin: pharmacokinetics A post-marketing study in Japanese epileptic patients with renal impairment	Pfizer
8 700006410	Antiparkinsonians Catechol-O-methyltransferase-inhibitors Dopamine-receptor-agonists Levodopa Monoamine-oxidase-B-inhibitors	Active, no longer recruiting	IV	Antiparkinsonians: therapeutic use Parkinson's disease Phase IV trial of cost-effectiveness, cost-utility, cost-minimisation and quality-of-life effects: the PDMED study	
9 700041689	Dronabinol Modafinil	Active, no longer recruiting		Dronabinol + modafinil: pharmacodynamics Effect of modafinil on the cognitive, subjective, and physiological effects of marijuana	
10 700048538	Galantamine	Recruiting	I	Galantamine: therapeutic use Cognition disorders In Marijuana users	
11 700046398	Interferon-beta-1b	Recruiting	IV	Interferon beta-1b: adverse reactions Various toxicities In pediatric patients with multiple sclerosis	Bayer
12 700030764	Levodopa/carbidopa	Recruiting	III	Levodopa/carbidopa: adverse reactions Various toxicities Intestinal gel formulation in patients with advanced Parkinson's disease: phase III trial	Solvay Pharmaceuticals
13 700020302	Davunetide	Completed	II	Davunetide: therapeutic use Schizophrenia Phase II study in patients with cognitive impairment	Allon Therapeutics

CTI - Neurological Disorders January 2010



Adis CTI Record	Drug(s)	Study Status	Study Phase	Headline	Sponsor
14 700045547	Glatiramer-acetate	Recruiting	IV	Glatiramer acetate: therapeutic use Multiple sclerosis In patients with clinically isolated syndrome or early relapsing remitting disease	sanofi-aventis, Teva Pharmaceutical Industries
15 700048739	Lorazepam Methylphenidate Modafinil	Completed	I	Lorazepam vs methylphenidate vs modafinil: pharmacodynamics Effect on brain activity measured by magnetoencephalography, electroencephalography and the synchronous neural interaction test In volunteers	Orasi Medical
16 700028927	Pramipexole	Completed	II	Pramipexole: adverse reactions Various toxicities Comparison between extended-release and immediate-release in patients with Parkinson's disease on levodopa therapy	Boehringer Ingelheim
17 700033570	Rotigotine	Completed	II	Rotigotine: therapeutic use Restless legs syndrome In Japanese patients with idiopathic disease	Otsuka Pharmaceutical
18 700023600	BGC-200134	Completed	I	BGC 200134: adverse reactions Various toxicities Phase I trial in volunteers	BTG
19 700019846	Insulin	Active, no longer recruiting	III	Insulin: therapeutic use Stroke Effect on infarct size and neurological outcome	
20 700045120	Entacapone Levodopa/carbidopa Tolcapone	Completed	IV	Levodopa/carbidopa +/- entacapone, tolcapone: pharmacokinetics In patients with Parkinson's disease	
21 700051965	Rasagiline	Recruiting	IV	Rasagiline: therapeutic use Parkinson's-disease Effect on sleep disturbances in patients with idiopathic disease	Teva Neuroscience, Teva Pharmaceutical Industries
22 700047996	Interferon-beta-1a	Active, no longer recruiting	III	Interferon beta-1a: therapeutic use Multiple sclerosis In patients with relapsing disease	EMD Serono
23 700045886	Oxcarbazepine	Recruiting	III	Oxcarbazepine: adverse reactions Various toxicities In paediatric patients with refractory partial seizures	Supernus Pharmaceuticals

CTI - Neurological Disorders January 2010



Adis CTI Record	Drug(s)	Study Status	Study Phase	Headline	Sponsor
24 700026754	Rotigotine	Recruiting	III	Rotigotine: therapeutic use Parkinson's disease In patients with advanced stage disease taking stable dose levodopa	UCB
25 700033715	Rotigotine	Recruiting	II	Rotigotine: therapeutic use Stroke	
26 700046030	Oxcarbazepine	Recruiting	I	Oxcarbazepine: adverse reactions Various-toxicities In paediatric patients with refractory partial seizures	Supernus Pharmaceuticals
27 700048368	Moxifloxacin Talampanel	Active, no longer recruiting	I	Talampanel vs moxifloxacin: pharmacodynamics Effect on cardiac repolarization In volunteers	Teva Neuroscience, Teva Pharmaceutical Industries

For further information, please call +44 (0) 20 7981 0765 or send an e-mail to clientsupport@wolterskluwer.com.